{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:55:08Z","timestamp":1789577708843,"version":"build-2803163510"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002860","name":"China Sponsorship Council","doi-asserted-by":"publisher","award":["201708430104"],"award-info":[{"award-number":["201708430104"]}],"id":[{"id":"10.13039\/501100002860","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Androgen receptor (AR) plays a vital role in prostate cancer (PCa), including castration-resistant PCa, by retaining AR signalling. Androgen deprivation treatment (ADT) has been the standard treatment in the past decades. A great number of AR antagonists initially had been found effective in tumour remission; however, most PCa relapsed that caused by pre-translational resistance such as AR mutations to turn antagonist into agonist, and AR variants to bypass the androgen binding. Recently, several alternative therapeutic choices have been proposed. Among them, proteolysis targeting chimera (PROTAC) acts different from traditional drugs that usually function as inhibitors or antagonists, and it degrades oncogenic protein and does not disrupt the transcription of an oncogene. This review first discussed some essential mechanisms of ADT resistance, and then introduced the application of AR-targeted PROTAC in PCa cells, as well as other AR-targeted therapeutic choices.<\/jats:p>","DOI":"10.1007\/s12094-022-02957-x","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T19:30:06Z","timestamp":1665084606000},"page":"352-363","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The androgen receptor-targeted proteolysis targeting chimera and other alternative therapeutic choices in overcoming the resistance to androgen deprivation treatment in prostate cancer"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9762-4183","authenticated-orcid":false,"given":"Liuxun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1331-440X","authenticated-orcid":false,"given":"Jiangli","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"issue":"16","key":"2957_CR1","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.3390\/cancers13164107","volume":"13","author":"K Singh","year":"2021","unstructured":"Singh K, et al. The Pathophysiology and the therapeutic potential of cannabinoids in prostate cancer. Cancers. 2021;13(16):4107.","journal-title":"Cancers"},{"issue":"1","key":"2957_CR2","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12916-022-02453-7","volume":"20","author":"VJ Gnanapragasam","year":"2022","unstructured":"Gnanapragasam VJ, Greenberg D, Burnet N. Urinary symptoms and prostate cancer-the misconception that may be preventing earlier presentation and better survival outcomes. BMC Med. 2022;20(1):264.","journal-title":"BMC Med"},{"key":"2957_CR3","first-page":"1","volume":"40","author":"B Schulte","year":"2020","unstructured":"Schulte B, et al. Sorting through the maze of treatment options for metastatic castration-sensitive prostate cancer. Am Soc Clin Oncol Educ Book. 2020;40:1\u201310.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"8","key":"2957_CR4","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41416-021-01641-1","volume":"126","author":"SK Srivastava","year":"2022","unstructured":"Srivastava SK, et al. MYB interacts with androgen receptor, sustains its ligand-independent activation and promotes castration resistance in prostate cancer. Br J Cancer. 2022;126(8):1205\u201314.","journal-title":"Br J Cancer"},{"issue":"5","key":"2957_CR5","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.molcel.2020.06.031","volume":"79","author":"X Yu","year":"2020","unstructured":"Yu X, et al. Structural insights of transcriptionally active, full-length androgen receptor coactivator complexes. Mol Cell. 2020;79(5):812-823.e4.","journal-title":"Mol Cell"},{"issue":"1","key":"2957_CR6","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1038\/s41467-020-15815-7","volume":"11","author":"D Zhang","year":"2020","unstructured":"Zhang D, et al. Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer. Nat Commun. 2020;11(1):2089.","journal-title":"Nat Commun"},{"issue":"6","key":"2957_CR7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41594-019-0226-x","volume":"26","author":"F Ding","year":"2019","unstructured":"Ding F, Elowitz MB. Constitutive splicing and economies of scale in gene expression. Nat Struct Mol Biol. 2019;26(6):424\u201332.","journal-title":"Nat Struct Mol Biol"},{"issue":"3","key":"2957_CR8","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00345-018-02619-0","volume":"38","author":"S Wach","year":"2020","unstructured":"Wach S, Taubert H, Cronauer M. Role of androgen receptor splice variants, their clinical relevance and treatment options. World J Urol. 2020;38(3):647\u201356.","journal-title":"World J Urol"},{"issue":"2","key":"2957_CR9","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243\u201362.","journal-title":"Eur Urol"},{"issue":"1","key":"2957_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41391-018-0079-0","volume":"22","author":"ED Crawford","year":"2019","unstructured":"Crawford ED, et al. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis. 2019;22(1):24\u201338.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"2957_CR11","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3390\/cancers14040967","volume":"14","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, et al. Prospect of prostate cancer treatment: armed CAR-T or combination therapy. Cancers. 2022;14(4):967.","journal-title":"Cancers"},{"issue":"13","key":"2957_CR12","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/pros.23663","volume":"78","author":"P Barata","year":"2018","unstructured":"Barata P, et al. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy. Prostate. 2018;78(13):1035\u201341.","journal-title":"Prostate"},{"issue":"21","key":"2957_CR13","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.1158\/0008-5472.CAN-20-4028","volume":"81","author":"A El-Kenawi","year":"2021","unstructured":"El-Kenawi A, et al. Macrophage-derived cholesterol contributes to therapeutic resistance in prostate cancer. Cancer Res. 2021;81(21):5477\u201390.","journal-title":"Cancer Res"},{"issue":"Suppl 1","key":"2957_CR14","first-page":"S25","volume":"82","author":"EM Kwan","year":"2022","unstructured":"Kwan EM, Wyatt AW. Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer. Prostate. 2022;82(Suppl 1):S25-s36.","journal-title":"Prostate"},{"issue":"3","key":"2957_CR15","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.cell.2018.06.039","volume":"174","author":"DA Quigley","year":"2018","unstructured":"Quigley DA, et al. Genomic hallmarks and structural variation in metastatic prostate cancer. Cell. 2018;174(3):758-769.e9.","journal-title":"Cell"},{"issue":"6","key":"2957_CR16","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/bjc.2014.13","volume":"110","author":"S Merson","year":"2014","unstructured":"Merson S, et al. Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer. Br J Cancer. 2014;110(6):1655\u201362.","journal-title":"Br J Cancer"},{"issue":"2","key":"2957_CR17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/path.5652","volume":"254","author":"LH Porter","year":"2021","unstructured":"Porter LH, et al. Androgen receptor enhancer amplification in matched patient-derived xenografts of primary and castrate-resistant prostate cancer. J Pathol. 2021;254(2):121\u201334.","journal-title":"J Pathol"},{"issue":"7","key":"2957_CR18","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/s41419-022-05084-1","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen Y, et al. Second generation androgen receptor antagonists and challenges in prostate cancer treatment. Cell Death Dis. 2022;13(7):632.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2957_CR19","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3390\/jcm11010257","volume":"11","author":"FP Young","year":"2022","unstructured":"Young FP, et al. Biomarkers of castrate resistance in prostate cancer: androgen receptor amplification and T877A mutation detection by multiplex droplet digital PCR. J Clin Med. 2022;11(1):257.","journal-title":"J Clin Med"},{"key":"2957_CR20","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-22-0140","author":"M Shiota","year":"2022","unstructured":"Shiota M, et al. Androgen receptor mutations for precision medicine in prostate cancer. Endocr Relat Cancer. 2022. https:\/\/doi.org\/10.1530\/ERC-22-0140.","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"2957_CR21","doi-asserted-by":"publisher","first-page":"R143","DOI":"10.1530\/ERC-22-0140","volume":"29","author":"M Shiota","year":"2022","unstructured":"Shiota M, et al. Androgen receptor mutations for precision medicine in prostate cancer. Endocr Relat Cancer. 2022;29(10):R143-r155.","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"2957_CR22","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/humu.22046","volume":"33","author":"B Gottlieb","year":"2012","unstructured":"Gottlieb B, et al. The androgen receptor gene mutations database: 2012 update. Hum Mutat. 2012;33(5):887\u201394.","journal-title":"Hum Mutat"},{"issue":"7","key":"2957_CR23","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1158\/1535-7163.MCT-15-0892","volume":"15","author":"S Prekovic","year":"2016","unstructured":"Prekovic S, et al. The Effect of F877L and T878A mutations on androgen receptor response to enzalutamide. Mol Cancer Ther. 2016;15(7):1702\u201312.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2957_CR24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1677\/jme.0.0270309","volume":"27","author":"CW Gregory","year":"2001","unstructured":"Gregory CW, He B, Wilson EM. The putative androgen receptor-a form results from in vitro proteolysis. J Mol Endocrinol. 2001;27(3):309\u201319.","journal-title":"J Mol Endocrinol"},{"issue":"11","key":"2957_CR25","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.3390\/cancers13112563","volume":"13","author":"M Kanayama","year":"2021","unstructured":"Kanayama M, et al. AR splicing variants and resistance to AR targeting agents. Cancers. 2021;13(11):2563.","journal-title":"Cancers"},{"issue":"1","key":"2957_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40364-021-00276-x","volume":"9","author":"W Ouyang","year":"2021","unstructured":"Ouyang W, et al. Androgen receptor splice variant 7 detected by immunohistochemical is an independent poor prognostic marker in men receiving adjuvant androgen-deprivation therapy after radical prostatectomy. Biomark Res. 2021;9(1):23.","journal-title":"Biomark Res"},{"issue":"22","key":"2957_CR27","first-page":"11623","volume":"47","author":"L Duan","year":"2019","unstructured":"Duan L, et al. Histone lysine demethylase KDM4B regulates the alternative splicing of the androgen receptor in response to androgen deprivation. Nucleic Acids Res. 2019;47(22):11623\u201336.","journal-title":"Nucleic Acids Res"},{"issue":"23","key":"2957_CR28","doi-asserted-by":"publisher","first-page":"19736","DOI":"10.1074\/jbc.M112.352930","volume":"287","author":"SC Chan","year":"2012","unstructured":"Chan SC, Li Y, Dehm SM. Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J Biol Chem. 2012;287(23):19736\u201349.","journal-title":"J Biol Chem"},{"issue":"1","key":"2957_CR29","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.bbrc.2016.12.153","volume":"483","author":"D Nakata","year":"2017","unstructured":"Nakata D, et al. The RNA helicase DDX39B and its paralog DDX39A regulate androgen receptor splice variant AR-V7 generation. Biochem Biophys Res Commun. 2017;483(1):271\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"2957_CR30","doi-asserted-by":"publisher","first-page":"40957","DOI":"10.1038\/srep40957","volume":"7","author":"D Jones","year":"2017","unstructured":"Jones D, et al. Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer. Sci Rep. 2017;7:40957.","journal-title":"Sci Rep"},{"issue":"10","key":"2957_CR31","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1002\/ijc.30893","volume":"141","author":"B Wang","year":"2017","unstructured":"Wang B, et al. Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer. Int J Cancer. 2017;141(10):2121\u201330.","journal-title":"Int J Cancer"},{"issue":"22","key":"2957_CR32","doi-asserted-by":"publisher","first-page":"32210","DOI":"10.18632\/oncotarget.8493","volume":"7","author":"C Liu","year":"2016","unstructured":"Liu C, et al. Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer. Oncotarget. 2016;7(22):32210\u201320.","journal-title":"Oncotarget"},{"key":"2957_CR33","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.27861","author":"N Shah","year":"2017","unstructured":"Shah N, et al. Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. Elife. 2017. https:\/\/doi.org\/10.7554\/eLife.27861.","journal-title":"Elife"},{"issue":"4","key":"2957_CR34","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1158\/1078-0432.CCR-17-0989","volume":"24","author":"M Puhr","year":"2018","unstructured":"Puhr M, et al. The Glucocorticoid receptor is a key player for prostate cancer cell survival and a target for improved antiandrogen therapy. Clin Cancer Res. 2018;24(4):927\u201338.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2957_CR35","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","volume":"155","author":"VK Arora","year":"2013","unstructured":"Arora VK, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013;155(6):1309\u201322.","journal-title":"Cell"},{"issue":"11","key":"2957_CR36","first-page":"6235","volume":"37","author":"Y Yang","year":"2017","unstructured":"Yang Y, et al. Mifepristone has limited activity to enhance the in vivo efficacy of docetaxel and enzalutamide against bone metastatic and castration-resistant prostate cancer. Anticancer Res. 2017;37(11):6235\u201343.","journal-title":"Anticancer Res"},{"issue":"8","key":"2957_CR37","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1158\/1078-0432.CCR-21-4049","volume":"28","author":"AV Serritella","year":"2022","unstructured":"Serritella AV, et al. Phase I\/II trial of enzalutamide and mifepristone, a glucocorticoid receptor antagonist, for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2022;28(8):1549\u201359.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2957_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116691","volume":"10","author":"T Grindstad","year":"2015","unstructured":"Grindstad T, et al. High progesterone receptor expression in prostate cancer is associated with clinical failure. PLoS\u00a0One. 2015;10(2): e0116691.","journal-title":"PLoS\u00a0One"},{"issue":"1","key":"2957_CR39","doi-asserted-by":"publisher","first-page":"11358","DOI":"10.1038\/s41598-018-29520-5","volume":"8","author":"T Grindstad","year":"2018","unstructured":"Grindstad T, et al. Progesterone receptors in prostate cancer: progesterone receptor B is the isoform associated with disease progression. Sci Rep. 2018;8(1):11358.","journal-title":"Sci Rep"},{"issue":"6","key":"2957_CR40","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1158\/1078-0432.CCR-14-1220","volume":"21","author":"EJ Chen","year":"2015","unstructured":"Chen EJ, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273\u201380.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2957_CR41","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0002-9440(10)65160-7","volume":"155","author":"H Bonkhoff","year":"1999","unstructured":"Bonkhoff H, et al. Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am J Pathol. 1999;155(2):641\u20137.","journal-title":"Am J Pathol"},{"issue":"2","key":"2957_CR42","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41391-018-0081-6","volume":"22","author":"RW Dobbs","year":"2019","unstructured":"Dobbs RW, et al. Estrogens and prostate cancer. Prostate Cancer Prostatic Dis. 2019;22(2):185\u201394.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"2957_CR43","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.celrep.2019.02.111","volume":"27","author":"E Toska","year":"2019","unstructured":"Toska E, et al. PI3K inhibition activates SGK1 via a feedback loop to promote chromatin-based regulation of er-dependent gene expression. Cell rep. 2019;27(1):294-306 e5.","journal-title":"Cell rep"},{"issue":"6467","key":"2957_CR44","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1126\/science.aax3769","volume":"366","author":"C Pohl","year":"2019","unstructured":"Pohl C, Dikic I. Cellular quality control by the ubiquitin-proteasome system and autophagy. Science. 2019;366(6467):818\u201322.","journal-title":"Science"},{"issue":"3","key":"2957_CR45","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1002\/jcp.30011","volume":"236","author":"M Sarfraz","year":"2021","unstructured":"Sarfraz M, et al. Multifaceted behavior of PEST sequence enriched nuclear proteins in cancer biology and role in gene therapy. J Cell Physiol. 2021;236(3):1658\u201376.","journal-title":"J Cell Physiol"},{"issue":"3","key":"2957_CR46","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s12272-012-0301-x","volume":"35","author":"JH Lee","year":"2012","unstructured":"Lee JH, Lee MJ. Emerging roles of the ubiquitin-proteasome system in the steroid receptor signaling. Arch Pharm Res. 2012;35(3):397\u2013407.","journal-title":"Arch Pharm Res"},{"issue":"8","key":"2957_CR47","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1158\/1541-7786.MCR-17-0062","volume":"15","author":"S Sarkar","year":"2017","unstructured":"Sarkar S, Brautigan DL, Larner JM. Aurora kinase A promotes AR degradation via the E3 ligase CHIP. Mol Cancer Res. 2017;15(8):1063\u201372.","journal-title":"Mol Cancer Res"},{"issue":"4","key":"2957_CR48","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/pros.22763","volume":"74","author":"B Li","year":"2014","unstructured":"Li B, et al. Skp2 regulates androgen receptor through ubiquitin-mediated degradation independent of Akt\/mTOR pathways in prostate cancer. Prostate. 2014;74(4):421\u201332.","journal-title":"Prostate"},{"issue":"6","key":"2957_CR49","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41585-020-0314-z","volume":"17","author":"Z Wang","year":"2020","unstructured":"Wang Z, et al. The diverse roles of SPOP in prostate cancer and kidney cancer. Nat Rev Urol. 2020;17(6):339\u201350.","journal-title":"Nat Rev Urol"},{"issue":"41","key":"2957_CR50","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1038\/onc.2012.503","volume":"32","author":"A Felten","year":"2013","unstructured":"Felten A, et al. Zipper-interacting protein kinase is involved in regulation of ubiquitination of the androgen receptor, thereby contributing to dynamic transcription complex assembly. Oncogene. 2013;32(41):4981\u20138.","journal-title":"Oncogene"},{"issue":"9","key":"2957_CR51","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1158\/0008-5472.CAN-07-6059","volume":"68","author":"N Miyajima","year":"2008","unstructured":"Miyajima N, et al. TRIM68 regulates ligand-dependent transcription of androgen receptor in prostate cancer cells. Cancer Res. 2008;68(9):3486\u201394.","journal-title":"Cancer Res"},{"key":"2957_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112769","volume":"208","author":"AD Takwale","year":"2020","unstructured":"Takwale AD, et al. Design and characterization of cereblon-mediated androgen receptor proteolysis-targeting chimeras. Eur J Med Chem. 2020;208: 112769.","journal-title":"Eur J Med Chem"},{"issue":"D1","key":"2957_CR53","doi-asserted-by":"publisher","first-page":"D1381","DOI":"10.1093\/nar\/gkaa807","volume":"49","author":"G Weng","year":"2021","unstructured":"Weng G, et al. PROTAC-DB: an online database of PROTACs. Nucleic Acids Res. 2021;49(D1):D1381-d1387.","journal-title":"Nucleic Acids Res"},{"issue":"15","key":"2957_CR54","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1073\/pnas.141230798","volume":"98","author":"KM Sakamoto","year":"2001","unstructured":"Sakamoto KM, et al. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci USA. 2001;98(15):8554\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2957_CR55","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s41467-022-28520-4","volume":"13","author":"CH Ji","year":"2022","unstructured":"Ji CH, et al. The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system. Nat Commun. 2022;13(1):904.","journal-title":"Nat Commun"},{"key":"2957_CR56","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1080\/15548627.2022.2091338","volume":"18","author":"CH Ji","year":"2022","unstructured":"Ji CH, et al. Targeted protein degradation via the autophagy-lysosome system: AUTOTAC (AUTOphagy-TArgeting Chimera). Autophagy. 2022;18:2259\u201362.","journal-title":"Autophagy"},{"issue":"4","key":"2957_CR57","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1021\/acschembio.6b01068","volume":"12","author":"P Ottis","year":"2017","unstructured":"Ottis P, Crews CM. Proteolysis-targeting chimeras: induced protein degradation as a therapeutic strategy. ACS Chem Biol. 2017;12(4):892\u20138.","journal-title":"ACS Chem Biol"},{"key":"2957_CR58","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.pharmthera.2017.02.027","volume":"174","author":"TK Neklesa","year":"2017","unstructured":"Neklesa TK, Winkler JD, Crews CM. Targeted protein degradation by PROTACs. Pharmacol Ther. 2017;174:138\u201344.","journal-title":"Pharmacol Ther"},{"issue":"26","key":"2957_CR59","doi-asserted-by":"publisher","first-page":"7124","DOI":"10.1073\/pnas.1521738113","volume":"113","author":"K Raina","year":"2016","unstructured":"Raina K, et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc Natl Acad Sci USA. 2016;113(26):7124\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2957_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111952","volume":"187","author":"F Zhou","year":"2020","unstructured":"Zhou F, et al. Development of selective mono or dual PROTAC degrader probe of CDK isoforms. Eur J Med Chem. 2020;187: 111952.","journal-title":"Eur J Med Chem"},{"issue":"12","key":"2957_CR61","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1074\/mcp.T300009-MCP200","volume":"2","author":"KM Sakamoto","year":"2003","unstructured":"Sakamoto KM, et al. Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation. Mol Cell Proteom. 2003;2(12):1350\u20138.","journal-title":"Mol Cell Proteom"},{"issue":"1","key":"2957_CR62","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12918-017-0447-8","volume":"11","author":"RD Roy","year":"2017","unstructured":"Roy RD, Rosenmund C, Stefan MI. Cooperative binding mitigates the high-dose hook effect. BMC Syst Biol. 2017;11(1):74.","journal-title":"BMC Syst Biol"},{"issue":"2","key":"2957_CR63","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s00044-019-02485-4","volume":"29","author":"Y Da","year":"2019","unstructured":"Da Y, et al. Design, synthesis, and biological evaluation of small molecule PROTACs for potential anticancer effects. Med Chem Res. 2019;29(2):334\u201340.","journal-title":"Med Chem Res"},{"issue":"13","key":"2957_CR64","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1002\/pros.23874","volume":"79","author":"A Kaipainen","year":"2019","unstructured":"Kaipainen A, et al. Testosterone accumulation in prostate cancer cells is enhanced by facilitated diffusion. Prostate. 2019;79(13):1530\u201342.","journal-title":"Prostate"},{"key":"2957_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-018-0105-8","author":"J Salami","year":"2018","unstructured":"Salami J, et al. Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance. Commun Biol. 2018. https:\/\/doi.org\/10.1038\/s42003-018-0105-8.","journal-title":"Commun Biol"},{"issue":"1","key":"2957_CR66","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/aja.2008.26","volume":"11","author":"YQ Tang","year":"2009","unstructured":"Tang YQ, et al. Chimeric molecules facilitate the degradation of androgen receptors and repress the growth of LNCaP cells. Asian J Androl. 2009;11(1):119\u201326.","journal-title":"Asian J Androl"},{"issue":"24","key":"2957_CR67","doi-asserted-by":"publisher","first-page":"11218","DOI":"10.1021\/acs.jmedchem.9b01393","volume":"62","author":"X Han","year":"2019","unstructured":"Han X, et al. Discovery of highly potent and efficient PROTAC degraders of androgen receptor (AR) by employing weak binding affinity VHL E3 ligase ligands. J Med Chem. 2019;62(24):11218\u201331.","journal-title":"J Med Chem"},{"issue":"6_suppl","key":"2957_CR68","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1200\/JCO.2018.36.6_suppl.381","volume":"36","author":"T Neklesa","year":"2018","unstructured":"Neklesa T, et al. An oral androgen receptor PROTAC degrader for prostate cancer. J Clin Oncol. 2018;36(6_suppl):381\u20131.","journal-title":"J Clin Oncol."},{"issue":"2","key":"2957_CR69","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1021\/acs.jmedchem.8b01631","volume":"62","author":"X Han","year":"2019","unstructured":"Han X, et al. Discovery of ard-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer. J Med Chem. 2019;62(2):941\u201364.","journal-title":"J Med Chem"},{"issue":"21","key":"2957_CR70","doi-asserted-by":"publisher","first-page":"6001","DOI":"10.1158\/1078-0432.CCR-21-1819","volume":"27","author":"EA Mostaghel","year":"2021","unstructured":"Mostaghel EA, et al. Circulating and intratumoral adrenal androgens correlate with response to abiraterone in men with castration-resistant prostate cancer. Clin Cancer Res. 2021;27(21):6001\u201311.","journal-title":"Clin Cancer Res"},{"key":"2957_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-med-121211-091605","volume":"64","author":"R Ferraldeschi","year":"2013","unstructured":"Ferraldeschi R, et al. Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer. Annu Rev Med. 2013;64:1\u201313.","journal-title":"Annu Rev Med"},{"issue":"28","key":"2957_CR72","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","volume":"26","author":"G Attard","year":"2008","unstructured":"Attard G, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26(28):4563\u201371.","journal-title":"J Clin Oncol"},{"issue":"16","key":"2957_CR73","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1002\/pros.23236","volume":"76","author":"R Cathomas","year":"2016","unstructured":"Cathomas R, et al. Orteronel switch maintenance therapy in metastatic castration resistant prostate cancer after first-line docetaxel: a multicenter, randomized, double-blind, placebo-controlled trial (SAKK 08\/11). Prostate. 2016;76(16):1519\u201327.","journal-title":"Prostate"},{"issue":"6","key":"2957_CR74","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.eururo.2019.08.034","volume":"76","author":"ME Taplin","year":"2019","unstructured":"Taplin ME, et al. Androgen receptor modulation optimized for response-splice variant: a phase 3, randomized trial of galeterone versus enzalutamide in androgen receptor splice variant-7-expressing metastatic castration-resistant prostate cancer. Eur Urol. 2019;76(6):843\u201351.","journal-title":"Eur Urol"},{"issue":"20","key":"2957_CR75","doi-asserted-by":"publisher","first-page":"5731","DOI":"10.1158\/0008-5472.CAN-18-0941","volume":"78","author":"L Xiao","year":"2018","unstructured":"Xiao L, et al. epigenetic reprogramming with antisense oligonucleotides enhances the effectiveness of androgen receptor inhibition in castration-resistant prostate cancer. Cancer Res. 2018;78(20):5731\u201340.","journal-title":"Cancer Res"},{"issue":"10","key":"2957_CR76","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1038\/bjc.2013.619","volume":"109","author":"D Bianchini","year":"2013","unstructured":"Bianchini D, et al. First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. Br J Cancer. 2013;109(10):2579\u201386.","journal-title":"Br J Cancer"},{"issue":"7","key":"2957_CR77","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1172\/JCI66398","volume":"123","author":"JK Myung","year":"2013","unstructured":"Myung JK, et al. An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest. 2013;123(7):2948\u201360.","journal-title":"J Clin Invest"},{"issue":"17","key":"2957_CR78","doi-asserted-by":"publisher","first-page":"4466","DOI":"10.1158\/1078-0432.CCR-15-2901","volume":"22","author":"YC Yang","year":"2016","unstructured":"Yang YC, et al. Targeting androgen receptor activation function-1 with epi to overcome resistance mechanisms in castration-resistant prostate cancer. Clin Cancer Res. 2016;22(17):4466\u201377.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2957_CR79","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1634\/theoncologist.2016-0161","volume":"21","author":"ES Antonarakis","year":"2016","unstructured":"Antonarakis ES, et al. Targeting the N-terminal domain of the androgen receptor: a new approach for the treatment of advanced prostate cancer. Oncologist. 2016;21(12):1427\u201335.","journal-title":"Oncologist"},{"issue":"6","key":"2957_CR80","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.18632\/oncotarget.2924","volume":"6","author":"LJ Brand","year":"2015","unstructured":"Brand LJ, et al. EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer. Oncotarget. 2015;6(6):3811\u201324.","journal-title":"Oncotarget"},{"issue":"38","key":"2957_CR81","doi-asserted-by":"publisher","first-page":"26417","DOI":"10.1074\/jbc.M114.553818","volume":"289","author":"K Dalal","year":"2014","unstructured":"Dalal K, et al. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. J Biol Chem. 2014;289(38):26417\u201329.","journal-title":"J Biol Chem"},{"key":"2957_CR82","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.canlet.2018.08.016","volume":"437","author":"K Dalal","year":"2018","unstructured":"Dalal K, et al. Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer. Cancer Lett. 2018;437:35\u201343.","journal-title":"Cancer Lett"},{"key":"2957_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172783","volume":"866","author":"S Student","year":"2020","unstructured":"Student S, et al. Anti-androgen hormonal therapy for cancer and other diseases. Eur J Pharmacol. 2020;866: 172783.","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"2957_CR84","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/cen.12042","volume":"78","author":"M Frost","year":"2013","unstructured":"Frost M, et al. Similar reference intervals for total testosterone in healthy young and elderly men: results from the Odense Androgen study. Clin Endocrinol. 2013;78(5):743\u201351.","journal-title":"Clin Endocrinol"},{"issue":"7","key":"2957_CR85","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.3390\/cancers14071803","volume":"14","author":"H Iwamoto","year":"2022","unstructured":"Iwamoto H, et al. Androgen deprivation therapy in high-risk localized and locally advanced prostate cancer. Cancers. 2022;14(7):1803.","journal-title":"Cancers"},{"issue":"5","key":"2957_CR86","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.eururo.2015.12.005","volume":"69","author":"AL Kaplan","year":"2016","unstructured":"Kaplan AL, et al. Testosterone therapy in men with prostate cancer. Eur Urol. 2016;69(5):894\u2013903.","journal-title":"Eur Urol"},{"issue":"1","key":"2957_CR87","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4103\/1008-682X.160270","volume":"18","author":"R Kacker","year":"2016","unstructured":"Kacker R, et al. Can testosterone therapy be offered to men on active surveillance for prostate cancer? Prelim Results Asian J Androl. 2016;18(1):16\u201320.","journal-title":"Prelim Results Asian J Androl"},{"issue":"5\u20136","key":"2957_CR88","doi-asserted-by":"publisher","first-page":"181","DOI":"10.5489\/cuaj.3608","volume":"10","author":"AC Millar","year":"2016","unstructured":"Millar AC, et al. A survey of Canadian urologists\u2019 opinions and prescribing patterns of testosterone replacement therapy in men on active surveillance for low-risk prostate cancer. Can Urol Assoc J. 2016;10(5\u20136):181\u20134.","journal-title":"Can Urol Assoc J"},{"issue":"1","key":"2957_CR89","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/ijir.2012.29","volume":"25","author":"AW Pastuszak","year":"2013","unstructured":"Pastuszak AW, et al. Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res. 2013;25(1):24\u20138.","journal-title":"Int J Impot Res"},{"issue":"4","key":"2957_CR90","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/j.1743-6109.2009.01161.x","volume":"6","author":"M Khera","year":"2009","unstructured":"Khera M, et al. Testosterone replacement therapy following radical prostatectomy. J Sex Med. 2009;6(4):1165\u201370.","journal-title":"J Sex Med"},{"issue":"2","key":"2957_CR91","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1080\/13685538.2017.1298584","volume":"20","author":"A Yassin","year":"2017","unstructured":"Yassin A, et al. Is there a protective role of testosterone against high-grade prostate cancer? Incidence and severity of prostate cancer in 553 patients who underwent prostate biopsy: a prospective data register. Aging Male. 2017;20(2):125\u201333.","journal-title":"Aging Male"},{"issue":"2","key":"2957_CR92","doi-asserted-by":"publisher","DOI":"10.1590\/1678-4685-gmb-2019-0338","volume":"43","author":"JE Lee","year":"2020","unstructured":"Lee JE, Park CM, Kim JH. USP7 deubiquitinates and stabilizes EZH2 in prostate cancer cells. Genet Mol Biol. 2020;43(2): e20190338.","journal-title":"Genet Mol Biol"},{"issue":"16","key":"2957_CR93","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.1158\/1078-0432.CCR-17-0017","volume":"23","author":"M Kohli","year":"2017","unstructured":"Kohli M, et al. Androgen receptor variant AR-V9 is coexpressed with ar-v7 in prostate cancer metastases and predicts abiraterone resistance. Clin Cancer Res. 2017;23(16):4704\u201315.","journal-title":"Clin Cancer Res"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-022-02957-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-022-02957-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-022-02957-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T08:49:40Z","timestamp":1728118180000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-022-02957-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":93,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["2957"],"URL":"https:\/\/doi.org\/10.1007\/s12094-022-02957-x","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,6]]},"assertion":[{"value":"22 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have not disclosed any conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"It is not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"It is not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}